NCT00477412View on ClinicalTrials.gov

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 3, 2007

Primary Completion Date

October 28, 2020

Study Completion Date

October 28, 2020

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Bortezomib

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given PO or IV

DRUG

Doxorubicin

Given IV

DRUG

Methotrexate

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00477412 - Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter